vs
CULLEN/FROST BANKERS, INC.（CFR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是CULLEN/FROST BANKERS, INC.的1.3倍（$772.1M vs $580.9M），CULLEN/FROST BANKERS, INC.净利率更高（28.6% vs 12.7%，领先15.9%），CULLEN/FROST BANKERS, INC.同比增速更快（8.3% vs 5.9%），Revvity自由现金流更多（$161.8M vs $127.3M），过去两年Revvity的营收复合增速更高（9.0% vs 7.6%）
Frost Bank是总部位于美国圣安东尼奥的德克萨斯州特许银行，为银行控股公司卡伦/弗罗斯特银行家集团的核心子公司。其在得克萨斯州共设有200家营业网点、1750台自动柜员机，按总资产规模统计位列全美前60大银行之列。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CFR vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.3倍
$580.9M
营收增速更快
CFR
高出2.5%
5.9%
净利率更高
CFR
高出15.9%
12.7%
自由现金流更多
RVTY
多$34.5M
$127.3M
两年增速更快
RVTY
近两年复合增速
7.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $580.9M | $772.1M |
| 净利润 | $166.3M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 34.1% | 14.5% |
| 净利率 | 28.6% | 12.7% |
| 营收同比 | 8.3% | 5.9% |
| 净利润同比 | 7.4% | 3.9% |
| 每股收益（稀释后） | $2.56 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CFRRVTY
| Q4 25 | $580.9M | $772.1M | ||
| Q3 25 | $567.3M | $698.9M | ||
| Q2 25 | $546.9M | $720.3M | ||
| Q1 25 | $540.2M | $664.8M | ||
| Q4 24 | $536.3M | $729.4M | ||
| Q3 24 | $518.0M | $684.0M | ||
| Q2 24 | $507.9M | $691.7M | ||
| Q1 24 | $501.4M | $649.9M |
净利润CFRRVTY
| Q4 25 | $166.3M | $98.4M | ||
| Q3 25 | $174.4M | $46.7M | ||
| Q2 25 | $157.0M | $53.9M | ||
| Q1 25 | $150.9M | $42.2M | ||
| Q4 24 | $154.9M | $94.6M | ||
| Q3 24 | $146.5M | $94.4M | ||
| Q2 24 | $145.5M | $55.4M | ||
| Q1 24 | $135.7M | $26.0M |
毛利率CFRRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CFRRVTY
| Q4 25 | 34.1% | 14.5% | ||
| Q3 25 | 36.7% | 11.7% | ||
| Q2 25 | 34.1% | 12.6% | ||
| Q1 25 | 33.2% | 10.9% | ||
| Q4 24 | 34.3% | 16.3% | ||
| Q3 24 | 33.8% | 14.3% | ||
| Q2 24 | 34.5% | 12.4% | ||
| Q1 24 | 32.2% | 6.8% |
净利率CFRRVTY
| Q4 25 | 28.6% | 12.7% | ||
| Q3 25 | 30.7% | 6.7% | ||
| Q2 25 | 28.7% | 7.5% | ||
| Q1 25 | 27.9% | 6.4% | ||
| Q4 24 | 28.9% | 13.0% | ||
| Q3 24 | 28.3% | 13.8% | ||
| Q2 24 | 28.6% | 8.0% | ||
| Q1 24 | 27.1% | 4.0% |
每股收益（稀释后）CFRRVTY
| Q4 25 | $2.56 | $0.86 | ||
| Q3 25 | $2.67 | $0.40 | ||
| Q2 25 | $2.39 | $0.46 | ||
| Q1 25 | $2.30 | $0.35 | ||
| Q4 24 | $2.36 | $0.77 | ||
| Q3 24 | $2.24 | $0.77 | ||
| Q2 24 | $2.21 | $0.45 | ||
| Q1 24 | $2.06 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.6B | $7.3B |
| 总资产 | $53.0B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CFRRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
股东权益CFRRVTY
| Q4 25 | $4.6B | $7.3B | ||
| Q3 25 | $4.5B | $7.4B | ||
| Q2 25 | $4.2B | $7.6B | ||
| Q1 25 | $4.1B | $7.6B | ||
| Q4 24 | $3.9B | $7.7B | ||
| Q3 24 | $4.1B | $7.9B | ||
| Q2 24 | $3.7B | $7.9B | ||
| Q1 24 | $3.6B | $7.8B |
总资产CFRRVTY
| Q4 25 | $53.0B | $12.2B | ||
| Q3 25 | $52.5B | $12.1B | ||
| Q2 25 | $51.4B | $12.4B | ||
| Q1 25 | $52.0B | $12.4B | ||
| Q4 24 | $52.5B | $12.4B | ||
| Q3 24 | $51.0B | $12.8B | ||
| Q2 24 | $48.8B | $13.4B | ||
| Q1 24 | $49.5B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $274.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $127.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 21.9% | 21.0% |
| 资本支出强度资本支出/营收 | 25.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.65× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $116.4M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CFRRVTY
| Q4 25 | $274.0M | $182.0M | ||
| Q3 25 | $248.6M | $138.5M | ||
| Q2 25 | $140.8M | $134.3M | ||
| Q1 25 | $-296.1M | $128.2M | ||
| Q4 24 | $989.5M | $174.2M | ||
| Q3 24 | $307.2M | $147.9M | ||
| Q2 24 | $129.6M | $158.6M | ||
| Q1 24 | $488.4M | $147.6M |
自由现金流CFRRVTY
| Q4 25 | $127.3M | $161.8M | ||
| Q3 25 | $211.7M | $120.0M | ||
| Q2 25 | $114.5M | $115.5M | ||
| Q1 25 | $-337.1M | $112.2M | ||
| Q4 24 | $861.8M | $149.8M | ||
| Q3 24 | $281.9M | $125.6M | ||
| Q2 24 | $103.0M | $136.6M | ||
| Q1 24 | $450.3M | $129.7M |
自由现金流率CFRRVTY
| Q4 25 | 21.9% | 21.0% | ||
| Q3 25 | 37.3% | 17.2% | ||
| Q2 25 | 20.9% | 16.0% | ||
| Q1 25 | -62.4% | 16.9% | ||
| Q4 24 | 160.7% | 20.5% | ||
| Q3 24 | 54.4% | 18.4% | ||
| Q2 24 | 20.3% | 19.7% | ||
| Q1 24 | 89.8% | 20.0% |
资本支出强度CFRRVTY
| Q4 25 | 25.2% | 2.6% | ||
| Q3 25 | 6.5% | 2.6% | ||
| Q2 25 | 4.8% | 2.6% | ||
| Q1 25 | 7.6% | 2.4% | ||
| Q4 24 | 23.8% | 3.4% | ||
| Q3 24 | 4.9% | 3.3% | ||
| Q2 24 | 5.2% | 3.2% | ||
| Q1 24 | 7.6% | 2.7% |
现金转化率CFRRVTY
| Q4 25 | 1.65× | 1.85× | ||
| Q3 25 | 1.43× | 2.97× | ||
| Q2 25 | 0.90× | 2.49× | ||
| Q1 25 | -1.96× | 3.03× | ||
| Q4 24 | 6.39× | 1.84× | ||
| Q3 24 | 2.10× | 1.57× | ||
| Q2 24 | 0.89× | 2.87× | ||
| Q1 24 | 3.60× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CFR
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
